{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-23-000378","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.458064+00:00","generated_at":"2026-06-09T11:50:23.222385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Chemed Q3 revenue +7.2% to $565M; raises FY2023 adjusted EPS guidance to $19.82-$20.02","bullets":["GAAP diluted EPS $4.93 (+30.4% YoY); adjusted diluted EPS $5.32 (+24.9%).","VITAS net patient revenue $334M (+12.5%), ADC 18,859 (+9.4%), adjusted EBITDA margin 16.5% (+441 bps).","Roto-Rooter revenue $231M (+0.4%), adjusted EBITDA $66.9M (-3.7%), margin 29.0% (-124 bps).","Full-year adjusted EPS guidance raised to $19.82-$20.02 from $18.72-$18.92, includes $1.18/sh retention costs.","Ended quarter with $173M cash, no debt; repurchased $14.3M in shares at avg $504.07."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-23-000378","json":"https://secwatch.observer/filing/0001562762-23-000378.json","markdown":"https://secwatch.observer/filing/0001562762-23-000378.md","text":"https://secwatch.observer/filing/0001562762-23-000378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/0001562762-23-000378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/che-20230930x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:50:23.222385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24e5a245228a5fa8df8c375e86881074a21f54d1","claim":"CHEMED CORP reported third quarter ended September 30, 2023 results: revenue $565 million, EPS $4.93. Guidance raised.","evidence_excerpt":"and after-tax expense for the Retention Program was $9.6 million and $7.1 million, respectively.  Results for Quarter Ended September 30, 2023  · Revenue increased 7.2% to $565 million · GAAP Diluted Earnings-per-Share (EPS) of $4.93, an increase of 30.4% · Adjusted Diluted EPS of $5.32, an increase of 24.9%   VITAS segment operating results: · Net Patient","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/0001562762-23-000378-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$565 million"},{"label":"EPS","value":"$4.93"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"feacc8a56ace68ba5649049ab05184b5355661dd","claim":"CHEMED CORP updated its quarter ended September 30, 2023 guidance (raised).","evidence_excerpt":"On October 25, 2023, Chemed Corporation issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/0001562762-23-000378-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}